A deterministic history of records added to PeptideScanner and preserved profile or record revisions connected through the reviewed Orforglipron identity.
Showing the latest 33 additions by PeptideScanner publication date; the complete connected record set remains available on the cross-source timeline. Most recent addition: November 17, 2026.
The official Drugs@FDA dataset lists original submission 1 for NDA 220934 with status AP dated 2026-04-01, and names orforglipron calcium among the application record's active ingredients.
PeptideScanner retained ClinicalTrials.gov record NCT05869903 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-08-14, and PeptideScanner's reviewed identity mapping was orforglipron.
PeptideScanner retained ClinicalTrials.gov record NCT05872620 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-09-04, and PeptideScanner's reviewed identity mapping was orforglipron.
PeptideScanner retained ClinicalTrials.gov record NCT05931380 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-07-20, and PeptideScanner's reviewed identity mapping was orforglipron.
PeptideScanner retained ClinicalTrials.gov record NCT05971940 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-09-03, and PeptideScanner's reviewed identity mapping was orforglipron.
PeptideScanner retained ClinicalTrials.gov record NCT06010004 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-06-30, and PeptideScanner's reviewed identity mapping was orforglipron.
PeptideScanner retained ClinicalTrials.gov record NCT06109311 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-10-01, and PeptideScanner's reviewed identity mapping was orforglipron.
PeptideScanner retained ClinicalTrials.gov record NCT06186622 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-05-22, and PeptideScanner's reviewed identity mapping was orforglipron.
PeptideScanner retained ClinicalTrials.gov record NCT06192108 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-10-16, and PeptideScanner's reviewed identity mapping was orforglipron.
PeptideScanner retained ClinicalTrials.gov record NCT06370728 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-07-17, and PeptideScanner's reviewed identity mapping was orforglipron.
PeptideScanner retained ClinicalTrials.gov record NCT06440980 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-07-17, and PeptideScanner's reviewed identity mapping was orforglipron.
PeptideScanner retained ClinicalTrials.gov record NCT06649045 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-09-14, and PeptideScanner's reviewed identity mapping was orforglipron.
PeptideScanner retained ClinicalTrials.gov record NCT06672549 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-11-04, and PeptideScanner's reviewed identity mapping was orforglipron.
PeptideScanner retained ClinicalTrials.gov record NCT06672939 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-11-04, and PeptideScanner's reviewed identity mapping was orforglipron.
PeptideScanner retained ClinicalTrials.gov record NCT06704763 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-05-26, and PeptideScanner's reviewed identity mapping was orforglipron.
PeptideScanner retained ClinicalTrials.gov record NCT06972459 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-07-29, and PeptideScanner's reviewed identity mapping was orforglipron.
PeptideScanner retained ClinicalTrials.gov record NCT06993792 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-07-31, and PeptideScanner's reviewed identity mapping was orforglipron.
PeptideScanner retained ClinicalTrials.gov record NCT07153471 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-10-08, and PeptideScanner's reviewed identity mapping was orforglipron.
PeptideScanner retained ClinicalTrials.gov record NCT07202884 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-11-04, and PeptideScanner's reviewed identity mapping was orforglipron.
PeptideScanner retained ClinicalTrials.gov record NCT07223593 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-11-04, and PeptideScanner's reviewed identity mapping was orforglipron.
PeptideScanner retained ClinicalTrials.gov record NCT07241390 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-11-04, and PeptideScanner's reviewed identity mapping was orforglipron.
PeptideScanner retained ClinicalTrials.gov record NCT07613307 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-10-08, and PeptideScanner's reviewed identity mapping was orforglipron.
PeptideScanner retained ClinicalTrials.gov record NCT07729332 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-07-27, and PeptideScanner's reviewed identity mapping was orforglipron.
PeptideScanner retained ClinicalTrials.gov record NCT07739537 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-08-31, and PeptideScanner's reviewed identity mapping was orforglipron.
PeptideScanner retained ClinicalTrials.gov record NCT07790861 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-10-13, and PeptideScanner's reviewed identity mapping was orforglipron.
PeptideScanner retained ClinicalTrials.gov record NCT07794579 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-11-05, and PeptideScanner's reviewed identity mapping was orforglipron.
PubMed lists PMID 38091541 in The New England journal of medicine as Letter, Comment, with publication-date metadata of 2023-12-14 (day precision). PeptideScanner associated the retained record with the identity slug orforglipron. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 38091542 in The New England journal of medicine as Letter, Comment, with publication-date metadata of 2023-12-14 (day precision). PeptideScanner associated the retained record with the identity slug orforglipron. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 38091543 in The New England journal of medicine as Letter, Comment, with publication-date metadata of 2023-12-14 (day precision). PeptideScanner associated the retained record with the identity slug orforglipron. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 41994902 in Diabetes, obesity & metabolism as Clinical Trial, Phase I, Journal Article, Multicenter Study, Randomized Controlled Trial, with publication-date metadata of 2026-04-17 (day precision). PeptideScanner associated the retained record with the identity slug orforglipron. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 42138709 in American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists as Journal Article, with publication-date metadata of 2026-07-22 (day precision). PeptideScanner associated the retained record with the identity slug orforglipron. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 42420063 in Trends in pharmacological sciences as Journal Article, with publication-date metadata of 2026-07-08 (day precision). PeptideScanner associated the retained record with the identity slug orforglipron. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 43002163 in JAMA as Journal Article, with publication-date metadata of 2026-11-09 (day precision). PeptideScanner associated the retained record with the identity slug orforglipron. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.